‎Abzena appoints Geoffrey Glass as  CEO

Abzena, a leading end-to-end integrated contract development and manufacturing organization (CDMO) and contract research organization (CRO) specializing in complex biologics and bioconjugates, announced today that Geoffrey M. Glass has been named Chief Executive Officer (CEO), effective immediately.

‎

‎Glass, who has served as Chairman of the Board since 2022, brings a wealth of experience to the role.

‎

‎With over 30 years in the life sciences industry, Glass has held executive positions at prominent organizations, including EY Consulting, Valeant Pharmaceuticals (now Bausch Health), Patheon (now Thermo Fisher Scientific), Sancilio Pharmaceuticals, and KINICITI. His extensive background includes significant contributions to the growth of the CDMO sector over the past 15 years.

‎

‎”Abzena has made tremendous strides in operational excellence and advancing our scientific capabilities, which has driven significant growth and delighted our customers,” Glass said. “As Chairman, I’ve had the privilege of working with this exceptional team, and I’m honored to step into the CEO role to continue this momentum. I look forward to collaborating closely with our talented employees to support our customers and their patients.”

‎ALSO READ: LAFARGE AFRICA APRROVES UNICAM, ATLASS CEMENT MERGER

‎The Board of Directors praised Glass’s leadership, stating, “Geoff has been a steady and strategic leader as Chairman. His deep industry experience, operational focus, and customer-centric approach make him the ideal choice to lead Abzena into its next chapter. The company is well-positioned, and we are confident in Geoff’s ability to build on its success.”

‎

‎Abzena’s appointment of Glass signals its commitment to sustaining growth and innovation in the biologics and bioconjugates sector, as the company continues to support its global customer base and their critical work in advancing patient care.